Literature DB >> 3820220

Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analogue of apomorphine.

C S Schneider, J Mierau.   

Abstract

The enantiomers of the aminothiazole analogues of the known dopaminergic agonists apomorphine (1) and 2-aminohydroxytetralin (2) have been prepared. The absolute configurations of the enantiomers of 2,6-diaminotetrahydrobenzothiazole have been established by X-ray crystallographic analysis. Dopamine (DA) autoreceptor agonist activities of the compounds were evaluated. Testing revealed (-)-5, the S enantiomer, to be the most active compound tested (inhibition of GBL accelerated dopamine synthesis and inhibition of alpha-methyltyrosine-induced decline of DA). In addition (-)-5 does not exhibit stereotyped behavior, suggesting a pronounced selectivity for DA autoreceptors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3820220     DOI: 10.1021/jm00386a009

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Antidepressant effects of pramipexole, a novel dopamine receptor agonist.

Authors:  J Maj; Z Rogóz; G Skuza; K Kołodziejczyk
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  Developing Photoaffinity Probes for Dopamine Receptor D2 to Determine Targets of Parkinson's Disease Drugs.

Authors:  Spencer T Kim; Emma J Doukmak; Raymond G Flax; Dylan J Gray; Victoria N Zirimu; Ebbing de Jong; Rachel C Steinhardt
Journal:  ACS Chem Neurosci       Date:  2022-10-02       Impact factor: 5.780

3.  Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole.

Authors:  P Willner; S Lappas; S Cheeta; R Muscat
Journal:  Psychopharmacology (Berl)       Date:  1994-08       Impact factor: 4.530

4.  Synthesis and identification of a new class of (S)-2,6-diamino-4,5,6,7-tetrahydrobenzo[d]thiazole derivatives as potent antileukemic agents.

Authors:  D S Prasanna; C V Kavitha; B Raghava; K Vinaya; S R Ranganatha; Sathees C Raghavan; K S Rangappa
Journal:  Invest New Drugs       Date:  2009-06-10       Impact factor: 3.850

5.  Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease.

Authors:  Banibrata Das; Seenuvasan Vedachalam; Dan Luo; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2015-11-30       Impact factor: 7.446

Review 6.  From Riluzole to Dexpramipexole via Substituted-Benzothiazole Derivatives for Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies.

Authors:  Serge Mignani; Jean-Pierre Majoral; Jean-François Desaphy; Giovanni Lentini
Journal:  Molecules       Date:  2020-07-22       Impact factor: 4.411

7.  Solution-phase synthesis of a combinatorial library of 3-[4-(coumarin-3-yl)-1,3-thiazol-2-ylcarbamoyl]propanoic acid amides.

Authors:  Irina O Zhuravel; Sergiy M Kovalenko; Sergiy V Vlasov; Valentin P Chernykh
Journal:  Molecules       Date:  2005-02-28       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.